“We are very glad that India is embarking on vaccine exports. However, we are yet to know the number of doses Africa will receive,” said Dr John Nkengasong, who heads the Africa CDC, during a virtual press conference.
India was a key vaccine exporter to Africa before it stopped the exportation to focus on fighting the local infections. Now the African Union says India’s resumption of vaccine exports means the continent has to directly engage with the country on supplies.
As per the official agreement from last year, the Serum Institute of India (SII), which is the largest vaccine maker in the world, was expected to supply a billion doses to the low and middle-income countries.
The vaccine maker was required to provide 400 million vaccine doses in 2020 alone through Gavi, the international vaccine alliance of which the World Health Organisation (WHO) is a member.
This commitment did not materialize, following a surge in Covid cases in India, which prompted the Indian government to ban exportation of vaccine and prioritize her citizens.
After exporting 66.3 million doses by April 16, this year, which were touted by the Indian government as Vaccine Maitri (vaccine friendship), meant to position India as a vaccine-manufacturing hub, the initiative has since been halted.
The global heath body further explained that with inadequate vaccine supply, many countries and especially in Africa remained extremely susceptible to new strains of Covid-19, including B.1.617.2, which was first discovered in India.
Last week, Kenya’s Health Cabinet Secretary Mutahi Kagwe asked India, which also has a ‘fill and finish’ deal in place with Johnson and Johnson (J&J), to remember her obligations to prioritize meeting her Covax commitments and obligations despite their own challenges.
However, the SII Chief Executive Officer (CEO) Adar Poonawalla said that it is crucial for nations depending on India for vaccines to remember that the country is also a low-income country.
“Our exports to Covax will recommence again in October. However, we will only manage to export in large quantities in January 2022 to Covax after local demand has been met,” Poonawalla said.
Dr Nkengasong further disclosed that the AU is engaged in ongoing discussions with Western governments over intellectual property (IP) rights, so that Africa can manufacture her own vaccines.
“What we, however, need now are vaccines. Since we started the vaccination exercise, 200 million doses have been supplied to 55 AU member states with 115 million doses being used up, amounting to 76 per cent. However, those who are fully vaccinated or have received both the first and second jab are 4.5 per cent,” he highlighted.